Vericel Corp financial data

Symbol
VCEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
64 Sidney St., Cambridge, MA
State of incorporation
MI
Fiscal year end
December 31
Former names
AASTROM BIOSCIENCES INC (to 11/14/2014)
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 460 % -10.8%
Quick Ratio 35.8 % -4.84%
Debt-to-equity 51.7 % +0.25%
Return On Equity 4.04 %
Return On Assets 2.66 %
Operating Margin 1.9 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50M shares +2.81%
Common Stock, Shares, Outstanding 49.6M shares +3.76%
Entity Public Float 2.2B USD +24%
Common Stock, Value, Issued 685M USD +8.83%
Weighted Average Number of Shares Outstanding, Basic 48.8M shares +2.64%
Weighted Average Number of Shares Outstanding, Diluted 51.7M shares +8.59%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 237M USD +20.1%
Revenue from Contract with Customer, Excluding Assessed Tax 237M USD +20.1%
Research and Development Expense 24.8M USD +17.8%
Operating Income (Loss) 4.52M USD +45.2%
Nonoperating Income (Expense) 5.99M USD +46.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -901K USD +77.2%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 10.4M USD +52.4%
Earnings Per Share, Basic 0.21 USD/shares +46.4%
Earnings Per Share, Diluted 0.2 USD/shares +42.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 74.5M USD +7.86%
Accounts Receivable, after Allowance for Credit Loss, Current 61.4M USD +5.17%
Inventory, Net 17.4M USD +32.8%
Other Assets, Current 7.29M USD +6.33%
Assets, Current 213M USD +3.48%
Operating Lease, Right-of-Use Asset 70.1M USD -4.58%
Other Assets, Noncurrent 556K USD -27.9%
Assets 433M USD +22.4%
Accounts Payable, Current 23.8M USD +6.72%
Employee-related Liabilities, Current 3.27M USD -6.68%
Accrued Liabilities, Current 17.1M USD -0.87%
Liabilities, Current 50.3M USD +9.92%
Operating Lease, Liability, Noncurrent 89.6M USD +9.45%
Other Liabilities, Noncurrent 876K USD +776%
Liabilities 141M USD +10.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax 4K USD
Retained Earnings (Accumulated Deficit) -393M USD +2.57%
Stockholders' Equity Attributable to Parent 292M USD +29.2%
Liabilities and Equity 433M USD +22.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 7.2M USD -8.37%
Net Cash Provided by (Used in) Financing Activities 2.13M USD +1887%
Net Cash Provided by (Used in) Investing Activities -25.5M USD -1009%
Common Stock, Shares Authorized 75M shares 0%
Common Stock, Shares, Issued 49.6M shares +3.76%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.1M USD -250%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 85M USD -2.09%
Deferred Tax Assets, Valuation Allowance 45.2M USD -9.25%
Deferred Tax Assets, Gross 73.8M USD +4.43%
Operating Lease, Liability 98.9M USD
Depreciation 4.9M USD +22.5%
Payments to Acquire Property, Plant, and Equipment 14M USD +892%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 10.5M USD +45.6%
Lessee, Operating Lease, Liability, to be Paid 145M USD
Operating Lease, Liability, Current 9.26M USD +49.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 14M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 13.7M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 42M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 14.4M USD
Deferred Tax Assets, Operating Loss Carryforwards 15.5M USD +244%
Lessee, Operating Lease, Liability, to be Paid, Year Four 14.7M USD
Depreciation, Depletion and Amortization 1.38M USD +19%
Interest Expense 608K USD +23.3%